Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Reporter, APAC, Pharma insights
South Korea
+6 year(s) experience
Jung Won has worked previously for Dow Jones Newswires, covering various industry sectors and the economy, providing her with an ability to work to tight deadlines. She has played a key role in expanding Scrip and Pink Sheet's coverage of the important South Korean market, including biosimilar companies, emerging bioventures, and important policy, pricing and regulatory developments.
Scrip
Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds.
Generics Bulletin
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
Topic Coronavirus
Scrip
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Topic Clinical Trials Deal trends
Scrip
AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.
Topic Company analysis Strategy
Scrip
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Topic FDA Business strategies
Scrip
South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen from public disclosures, and have ordered further investigation of a corporate governance decision on the handling in accounts of the JV, Samsung Bioepis. The latest ruling in the prolonged affair could hurt the credibility and business of Samsung BioLogics going forward, although the firm maintains it has done nothing improper.
Topic Policy and regulation
Scrip
Application of artificial intelligence to new drug development in South Korea, which has been lagging in this area, is poised to accelerate as the country moves to support and encourage the technology.
Scrip
The Korean biotech’s CEO and other executives’ alleged involvement in stock price manipulation has damaged R&D credibility and shocked the domestic industry
Scrip
As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests.
Scrip
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda.
Topic Biosimilars
Pink Sheet
Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.
Topic Biosimilars Drug review
Scrip
29 Jul 2021
Scrip
26 Jul 2021
Scrip
01 Jul 2021
Scrip
29 Jun 2021
Scrip
22 Jun 2021
Scrip
14 Jun 2021
Scrip
01 Jun 2021
Scrip
13 May 2021
Scrip
07 May 2021
Pink Sheet
30 Apr 2021
Pink Sheet
26 Apr 2021
Scrip
21 Apr 2021
Scrip
12 Apr 2021
Scrip
01 Apr 2021
Generics Bulletin
30 Mar 2021
